We know that risk for conversion from mild cognitive impairment to the dementia stage of AD is increased in patients with elevated concentrations of the pro-inflammatory cytokine TNF-α and decreased concentrations of anti-inflammatory transforming growth factor beta (TGF-β) in the CSF. This evidence concerns the gene TGFB1 and Alzheimer disease.